4D pharma (DDDD) Share Price, News & Analysis

Company Overview

4D pharma plc, together with its subsidiaries, develops live biotherapeutic products (LBPs) in the United Kingdom. The company develops therapeutic candidates, including MRx0518 for the treatment of cancer and immune-oncology diseases; MRx-4DP0004 for the treatment of asthma; MRx0029 and MRx0005 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, such as MRx1299 for solid tumors, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. In addition, the company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck KGaA, Darmstadt, Germany and Pfizer to evaluate MRx0518; strategic collaboration agreement with University of Texas MD Anderson for discovery and development of LBPs in oncology; and Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda, MRx0518 in patients with solid tumors, and to discover and develop LBPs for vaccines. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom.

Key Stats

• Today's Range: 16.66 to 16.66
• 50-Day Range: 16.66 to 16.66
• 52-Week Range: 16.66 to 16.66
• Volume: 1.21 million shs
• Average Volume: 2.96 million shs
• Market Capitalization: £30.04 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

DDDD Stock Analysis - Frequently Asked Questions

How have DDDD shares performed this year?

4D pharma's stock was trading at GBX 16.66 at the start of the year. Since then, DDDD shares have increased by 0.0% and is now trading at GBX 16.66.
View the best growth stocks for 2024 here.

How were 4D pharma's earnings last quarter?

4D pharma plc (LON:DDDD) posted its earnings results on Wednesday, September, 30th. The company reported ($14.06) earnings per share for the quarter.

How do I buy shares of 4D pharma?

Shares of DDDD stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What other stocks do shareholders of 4D pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that 4D pharma investors own include Omega Diagnostics Group (ODX), Tullow Oil (TLW), B&M European Value Retail (BME), BP (BP), Coats Group (COA), genedrive (GDR) and Greencore Group (GNC).

Company Calendar

• Last Earnings: 9/30/2020
• Today: 11/21/2024

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: LON:DDDD
• CUSIP: N/A
• CIK: N/A
• Web: www.4dpharmaplc.com
• Phone: +44-113-8950130
• Fax: N/A
• Employees: 106
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX (15.40)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: £-31,940,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -89.48%
• Return on Assets: -42.64%

Debt

• Debt-to-Equity Ratio: 39.50
• Current Ratio: 5.21
• Quick Ratio: 4.72

Sales & Book Value

• Annual Sales: £718,000.00
• Price / Sales: 41.84
• Cash Flow: GBX 11.60 per share
• Price / Cash Flow: 1.44
• Book Value: GBX 18 per share
• Price / Book: 0.93

Miscellaneous

• Outstanding Shares: 180,340,000
• Free Float: N/A
• Market Cap: £30.04 million
• Optionable: Not Optionable
• Beta: 2.63